Study of Innate Host Immune Response to C. Glabrata Clinical Isolates Resistant to Echinocandins: Impact on the Management of Candidemia in High-risk Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

21 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-01

Study Completion Date

2019-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the context of Candida yeast infections, a large number of studies have been published over the past two decades specifying the molecular mechanisms of antifungal resistance in different Candida species. However, few of these studies have explored how these mechanisms influence host immune response to this opportunistic pathogen. Recent advances in understanding how the host's immune system responds to Candida have initiated the emergence of a new research theme aimed at better understanding Candida's intrinsic and adaptive resistance mechanisms to antifungals can modulate "escape to" or "recognition by" the host's immune system. This knowledge could lead to (i) a better understanding of the predominance of certain Candida species with antifungal resistance in certain patient populations, (ii) a better understanding of why high levels of in vitro resistance are not necessarily correlated with in vivo therapeutic failure, and (iii) effective immunotherapeutic strategies to control Candida resistance to antifungals.

It is therefore crucial to investigate the impact of Candida's resistance to antifungals on the host's innate immune response. Indeed, most antifungal resistance mechanisms have a direct or indirect structural modification of the fungal wall. However, it is the composition of this wall that is involved in the recognition of Candida by the host cell via the pattern recognition receptors (PRRs). We therefore put forward the very probable hypothesis that changes in the fungal wall, induced by the appearance of resistance, could alter the recognition of Candida by PRRs and thus trigger a different immune response, either qualitatively (type of cytokines secreted) or quantitatively (amplitude and duration of the immune response). However, even if initial experimental data support the hypothesis of a possible link between resistance and a modulation of the innate immune response in digestive mucosa (the most frequent starting point for disseminated candidiasis), many questions remain regarding (i) the proteins and mechanisms of the modulated immune cascade, (ii) the modification of the immune response according to the Candida species in question and (iii) the modification of the immune response according to the resistance phenotype in question.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Antibiotic-induced Vaginal Yeast Infections in Healthy Women

NCT01915251

Microbiome Antibiotic-Induced VVC Vaginal Candidiasis

TERMINATED

A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia

NCT06907992

Candidemia

NOT_YET_RECRUITING

Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins

NCT00839540

Candidemia

COMPLETED PHASE4

The Role of Interferon-gamma in Immune Responses to Invasive Candidiasis

NCT05235711

Fungal Infection Candidiasis

COMPLETED

Immunological Interaction Between the Host and Candida Albicans Biofilm

NCT01919931

Candidiasis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Candidemia of C. Glabrata

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Reference strain ATCC

1 strain sensitive to all antifungals

in vitro evaluation of epithelial immune response during C. glabrata infection

Intervention Type OTHER

1. study of the expression of genes coding for different proteins involved in the RTqPCR activation cascade
2. study of protein expression by the Western-Blot method

study of the impact of resistance phenotype acquisition on the virulence of C. glabrata isolates

Intervention Type OTHER

1. in vitro evaluation by measuring cell invasion, cell adhesion and by determining epithelial cell cytotoxicity.
2. in vivo evaluation measured by a survival study on a CD-1 mouse model.

Clinical isolates sensitive to all antifungal agents

10 clinical isolates sensitive to all

in vitro evaluation of epithelial immune response during C. glabrata infection

Intervention Type OTHER

1. study of the expression of genes coding for different proteins involved in the RTqPCR activation cascade
2. study of protein expression by the Western-Blot method

study of the impact of resistance phenotype acquisition on the virulence of C. glabrata isolates

Intervention Type OTHER

1. in vitro evaluation by measuring cell invasion, cell adhesion and by determining epithelial cell cytotoxicity.
2. in vivo evaluation measured by a survival study on a CD-1 mouse model.

Echinocandin-resistant clinical isolates

10 echinocandin-resistant clinical isolates (Eucast, Caspofungin \> 8µg/ml)

in vitro evaluation of epithelial immune response during C. glabrata infection

Intervention Type OTHER

1. study of the expression of genes coding for different proteins involved in the RTqPCR activation cascade
2. study of protein expression by the Western-Blot method

study of the impact of resistance phenotype acquisition on the virulence of C. glabrata isolates

Intervention Type OTHER

1. in vitro evaluation by measuring cell invasion, cell adhesion and by determining epithelial cell cytotoxicity.
2. in vivo evaluation measured by a survival study on a CD-1 mouse model.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

in vitro evaluation of epithelial immune response during C. glabrata infection

1. study of the expression of genes coding for different proteins involved in the RTqPCR activation cascade
2. study of protein expression by the Western-Blot method

Intervention Type OTHER

study of the impact of resistance phenotype acquisition on the virulence of C. glabrata isolates

1. in vitro evaluation by measuring cell invasion, cell adhesion and by determining epithelial cell cytotoxicity.
2. in vivo evaluation measured by a survival study on a CD-1 mouse model.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 10 clinical isolates sensitive to all antifungal agents
* 10 echinocandin-resistant clinical isolates (Eucast, caspofungin \> 8µg/ml)

Clinical strains of C. glabrata susceptible or resistant to echinocandins will be selected on selected criteria:

* patient's immune status
* therapeutic management
* clinical developments